Biotech news
Pharma
For many of the key questions relating to the grant of SPCs, there is some variance in the practice of national patent offices, even where there is guidance from the CJEU, as Simon Spink and Adrian Chew of Bristows explain. 14 July 2016
Asia-Pacific
Several legislative changes affecting data exclusivity of biologic drugs in Vietnam are poised to come into effect, and companies operating in this sector should take note now, as Hien Thi Thu Vu and Huong Lan Nguyen of Tilleke & Gibbins explain. 14 July 2016
Americas
An en banc US Court of Appeals for the Federal Circuit said yesterday that two patents owned by The Medicines Company are valid in a case setting the rules for ‘on-sale’ product-by process patents. 12 July 2016
Americas
The US Food and Drug Administration has said that an Amgen biosimilar is indeed “highly similar” to AbbVie’s drug Humira in a document released for the advisory committee panel meeting due to be held tomorrow. 11 July 2016
Asia-Pacific
Legislative developments surrounding supplementary protection certificates in the EU are moving fast, and may be catching on as far afield as Australia. Gareth Morgan of Olswang explains more. 7 July 2016
Pharma
Following the UK’s vote to leave the EU, it is business as usual for life sciences companies working with intellectual property, at least for now, says Claire Phipps-Jones of Bristows. 7 July 2016
Americas
The US Court of Appeals for the Federal Circuit ruled yesterday in the Amgen v Apotex case that bisoimilars companies must always notify brand name rivals 180 days before launching their products. 6 July 2016
Americas
The Biotechnology Innovation Organisation has welcomed Hillary Clinton’s plans to improve the US’s patent system. 30 June 2016
Pharma
The UK’s vote to leave the EU has triggered an immediate need for innovative life sciences companies to evaluate the impact on their patent strategies, argues Laetitia Benard of Allen & Overy. 30 June 2016
Biotech
Is it time for healthcare regulators and patent offices to limit the strategies used by existing biologic manufacturers and allow new suppliers to reach some of the world’s most lucrative healthcare systems? Elizabeth Ward of Virtuoso Legal investigates. 30 June 2016